GILD vs BIIB — Key Metrics
| Metric | GILD (GILEAD SCIENCES INC) | BIIB (BIOGEN INC) |
|---|---|---|
| Price | 168.98 | 251.41 |
| Market Cap | 209.59 Billion | 37.16 Billion |
| P/E (TTM) | -54.51 | 106.53 |
| P/B (Quarterly) | 16.235 | 1.907 |
| P/S (TTM) | 6.76 | 3.61 |
| Net Profit Margin (TTM) | -12.5 | 3.4 |
| Gross Margin (TTM) | 79.9 | 74.0 |
| ROE (TTM) | -21.7 | 1.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Outperform
Recommendation Summary
Stock GILD is projected to outperform the market, stock BIIB is projected to greatly outperform the market. Upfront Recommendation: BIIB.
Financial Metrics
| GILD | Metrics | BIIB |
|---|---|---|
| $168.98 | Price | $251.41 |
| — | Market Capitalization | — |
| 6.76 | Price to Sales | 3.61 |
| 15.21 | Price to FCF Ratio | 18.09 |
| 8.46 | Price to Gross Profit | 4.88 |
| 33.12 | Price to R&D | 17.27 |
| 12.66 | Price to Current Assets | 4.9 |
GILD vs BIIB at a glance
Gilead Sciences INC (GILD) and Biogen INC (BIIB) are both Drug Manufacturers - General companies in the Healthcare sector. GILD is the larger, at $209.6 billion in market value against $37.2 billion for BIIB, about 5.6 times the size.
On trailing-twelve-month figures, GILD trades at 6.8 times trailing sales and BIIB at 3.6; net profit margins are -12.5% and 3.4%.
The Upfront Investment model currently rates GILD Outperform and BIIB Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.